← Compound index
COMPOUND RECORD / VENTFORT

VentfortВентфорт

A peptide mixture extracted from animal aorta, described in Russian reports on blood vessels and in dental patent cases.

Source linked

What the studies found

Comparison in people · 2006

Ventfort: clinical report on a tissue-derived preparation

The 2005–2006 report describes lipid and capillary-fragility outcomes during 10–15 days of adjunctive care.

Report attributed to · Medical Center, St. Petersburg Institute of Bioregulation and Gerontology

Study notes · methods, sources and limitations

Participants or model 49 patients: 27 adjunctive Ventfort; 22 controls; ages 52–84, atherosclerosis or senile purpura.

Important limitations

  • The table contains inconsistent sex subtotals. Lipid-table significance is relative to baseline; it does not establish fewer cardiovascular events. Commercially reproduced institute report; independent peer review and independent replication are not established by this document. Short-term reporting without a complete adverse-event protocol cannot establish long-term safety. Preparation equivalence to current products or synthetic peptides is unproven.

Institute clinical report (commercial reproduction); 2006 study/report date, not website publication date · Institute report — commercial reproduction

Original source or citation ↗

Study results and tables ↗

Comparison in people · 2021

Retinalamin with Cortexin and Ventfort Lingval in dry age-related macular degeneration

Study of multiple preparations

Visual acuity
Retinalamin alone 0.71 ± 0.05 to 0.76 ± 0.04. Combination 0.76 ± 0.05 to 0.88 ± 0.04.
Electroretinogram a-wave amplitude
Retinalamin alone 21.2 ± 1.5 to 28.1 ± 1.7 µV. Combination 21.4 ± 1.5 to 33.9 ± 1.5 µV.
Electroretinogram b-wave amplitude
Retinalamin alone 173.7 ± 8.1 to 222.7 ± 6.6 µV. Combination 172.8 ± 8.6 to 250.0 ± 7.3 µV.

Visual acuity went from 0.71 to 0.76 with Retinalamin alone and from 0.76 to 0.88 with the combination. This comparison used electrophoresis for the two added preparations.

Study notes · methods, sources and limitations

Participants or model 38 patients (76 eyes) with nonexudative macular degeneration: 20 Retinalamin alone, 18 the combination.

Design Five courses, repeated one to two times per year. The methods list temporal paravascular Retinalamin 5 mg daily for 10 days in both groups. In the combination group, Cortexin and Ventfort Lingval were given by cathodal drug electrophoresis daily for five days, 20 minutes per session at up to 0.1 mA/cm². Active mass for the two electrophoresis preparations was unspecified.

Important limitations

  • The report gives no randomization or masking method and the groups start with different acuity values. The contribution of each added preparation and electrophoresis cannot be isolated. The methods name Retinalamin but also describe Retilin in the adjacent text. The authors leave the mass applied by electrophoresis unspecified. The narrative percentages lack clear denominators. The tables contain no between-group p values or confidence intervals. Independent overlap with other retina cohorts is unspecified.
  • The combination adds two preparations and a different procedure. The report supplies no treatment-specific estimate for Cortexin or Ventfort Lingval and no between-group confidence intervals.

Vrach. 2021;32(5):85–87. · Original journal report

Original source or citation ↗

Study results and tables ↗

Comparison in people · 2013

Ventfort, Cerluten, Svetinorm and Endoluten in cerebral atherosclerosis

Study of multiple preparations

Total cholesterol
7.6 ± 0.3 mmol/L standard care, 6.3 ± 0.5 with two products, 5.8 ± 0.6 with four products. Shared baseline 8.7 ± 0.4.Both adjunctive groups are marked significant versus standard care. Exact p values are unavailable.
VLDL cholesterol
1.22 ± 0.06, 0.92 ± 0.07 and 0.87 ± 0.05 mmol/L, respectively. Shared baseline 1.42 ± 0.07.Both adjunctive groups are marked significant versus standard care.
Reported fatigue
64.0%, 32.3% and 12.9%, respectively. Shared baseline 75.6%.Only the four-product group is marked significant versus standard care in the fatigue row.

The conference table reports total cholesterol of 7.6 mmol/L with standard care, 6.3 with Ventfort and Cerluten, and 5.8 with the four-product combination.

Study notes · methods, sources and limitations

Participants or model 1,249 adults aged 55–65: 514 standard care, 319 standard care with Ventfort and Cerluten, 416 standard care with all four preparations.

Design Moscow, December 2011 to June 2012. Standard treatment alone (514), with Ventfort and Cerluten (319), or with those two plus Svetinorm and Endoluten (416). The Russian methods list two oral capsules each per day for three months for Ventfort, Cerluten and Svetinorm when assigned. Endoluten was one morning capsule daily for two months. Active mass per capsule is unspecified.

Important limitations

  • The authors excluded statin users and people with prior stroke. The comparison provides no individual estimates for Svetinorm or Endoluten. Both editions name Svetinorm in the four-product group and outcome tables. The English dosing list instead says Suprefort. The schedule below follows the Russian methods. The table gives one shared pretreatment column. Methods of allocation and masking, timing of the reported tables and adverse-event ascertainment are unspecified. Table 1 repeats the triglyceride heading with values of unclear identity. The cholesterol, VLDL and first triglyceride rows are legible. The Seoul report describes two comparisons from the same Moscow center. Recruitment dates overlap and participant-level linkage is unavailable.
  • The authors credit the St. Petersburg Institute of Bioregulation and Gerontology with developing the preparations. The comparison was conducted at the Moscow branch of the Centre for Revitalization and Health. Symptom assessment and statistical methods are incompletely reported. The Seoul report describes two comparisons from the same Moscow center. Recruitment dates overlap and participant-level linkage is unavailable.

20th IAGG World Congress, Seoul, 2013. Conference material reproduced by Peptides. · Conference report · company reproduction

Original source or citation ↗

Source for the reported results ↗

Study results and tables ↗
01 / OVERVIEW

About Ventfort

Identity / background source ↗

Research background

Ventfort is a vascular tissue peptide preparation studied for blood lipids, capillary fragility and urinary symptoms. The prostate study used a combination of preparations.

More study findings

Observational study · 2012

Oral peptide combinations for prostate symptoms in Agent Orange-exposed veterans

Study of multiple preparations

International Prostate Symptom Score
20.94 ± 8.49 → 8.46 ± 2.78p<0.01
Urinary flow
4.9 ± 2.3 → 9.1 ± 2.5 mL/sp<0.001
Urinary symptom quality-of-life item
4.10 ± 1.01 → 2.53 ± 0.61p<0.001

In 150 veterans, mean prostate symptom score (IPSS) fell from 20.94 to 8.46 (p<0.01) and urinary flow increased from 4.9 to 9.1 mL/s (p<0.001). This before-and-after comparison tested four oral products together.

More reported outcomes
Severe urinary symptoms
61/150 → 14/150IPSS ≥20. The paper reports 40.7% → 9.3%.
Study notes · methods, sources and limitations

Participants or model 150 veterans with benign prostatic hyperplasia. The same 150 are shown before and after treatment.

Design Prospective, within-person comparison of urinary symptoms, quality of life and urine flow before and after adjunctive treatment. All reported denominators below are 150 at each assessment.

Important limitations

  • There was no concurrent untreated comparator or single-product arm. The results cover the combination. The tested Veziliut lot and its peptide content remain unclear. The two 150-person publications are part of the same parent program, and participant overlap remains unverified.

Journal of Tropical Science and Technology. 2012;(1):85–93. · Publication record

Original source or citation ↗

Study results and tables ↗

Research updates ↗

Compound class
Tissue-derived peptide preparation
Research collection
Peptide bioregulation · editorial grouping
Institutions in linked studies
Medical Center, St. Petersburg Institute of Bioregulation and Gerontology
Source review
Review dates and the material assessed are listed with each publication below.
02 / HOW TO READ THE RESEARCH

Understanding the evidence

Human research

49 patients: 27 adjunctive Ventfort; 22 controls; ages 52–84, atherosclerosis or senile purpura.

Study methods

Small comparative institute report; allocation, blinding and outcome interpretation require caution

Independent replication

Independent replication not established in this collection

Source access

Report reproduction linked; source language and review scope shown per record

Safety evidence

Short-term reports do not establish long-term safety or equivalence to current products

Open a topic for the evidence assessment.

More findings, background and history

What remains unclear

The original report and protocol would clarify group sizes, background treatment and translation. Independent replication and equivalence to current products remain uncertain.

Human reports are linked; their presence does not establish effectiveness. Several publications can describe the same participants.

Browse original study records ↗

Explore the expanded peptide research collection and unresolved source trails ↗

View this preparation in the Khavinson evidence map ↗

PATENT RESEARCH / COLLECTION UPDATED 7 NOVEMBER 2026

Patents and claimed inventions

These 1 grouped records distinguish claimed molecules, uses, formulations and related chemistry. Patent disclosure does not establish clinical benefit or approval.

2016 · RU2593817C2 · Ventfort plus Chonsurid: dental bone-healing methodUse · 22 mm defect: healing at 6.5 months; density 211 HU

Reported findings

The Ventfort case had higher final density but slightly later reported healing, alongside a larger defect.

Ventfort adjunct case
22 mm defect: healing at 6.5 months; density 211 HUOne 63-year-old patient
Chonsurid-only example
14 mm defect: healing at 6 months; density 194 HUOne 64-year-old patient
All reported results, comparisons and limitations →

Use. The patent describes branded Ventfort in a combined dental-treatment approach.

The extract brand is not interchangeable with Vasolin, Slavinorm or purified KED, and combined treatment prevents independent attribution.

Publication
RU2593817C2 ↗ · 2016-08-10
Earliest priority / filing
2014-10-20 / 2014-10-20
Original applicant / assignee
Андрей Константинович Иорданишвили
Indexed status
Not shown; official status unverified · checked 2026-11-06
Patent family
56011738 · family publications are related filings, not independent studies.
Original title, inventors and related publications

Method of accelerating process of reparative osteogenesis

Inventors: Андрей Константинович Иорданишвили; Антон Анатольевич Сериков; Дмитрий Викторович Балин; Анна Геннадьевна Слугина; Владимир Владимирович Самсонов; Борис Лаврович Макеев; Ирина Борисовна Долгова.

RU2593817C2

Original patent PDF ↗

Read source review →

Status is an indexed snapshot, not an official legal assessment. Search the patent collection and read the method →

03 / SOURCE RECORDS

Findings by study

Tissue-preparation reports: comparisons, source limits and remaining gaps ↗

Explore related research ↗

Comparison in people · 2021

Retinalamin with Cortexin and Ventfort Lingval in dry age-related macular degeneration

Visual acuity went from 0.71 to 0.76 with Retinalamin alone and from 0.76 to 0.88 with the combination. This comparison used electrophoresis for the two added preparations.

Study notes and original source
2021Human comparative studyFull text available

Retinalamin with Cortexin and Ventfort Lingval in dry age-related macular degeneration

Temporal paravascular Retinalamin injections with or without Cortexin and Ventfort Lingval by electrophoresis · Original journal report

A. V. Derkach, S. V. Trofimova · Vrach. 2021;32(5):85–87.

Visual acuity went from 0.71 to 0.76 with Retinalamin alone and from 0.76 to 0.88 with the combination. This comparison used electrophoresis for the two added preparations.

Results and tables

Reported findings and study design

Five courses, repeated one to two times per year. The methods list temporal paravascular Retinalamin 5 mg daily for 10 days in both groups. In the combination group, Cortexin and Ventfort Lingval were given by cathodal drug electrophoresis daily for five days, 20 minutes per session at up to 0.1 mA/cm². Active mass for the two electrophoresis preparations was unspecified.

Population or model 38 patients (76 eyes) with nonexudative macular degeneration: 20 Retinalamin alone, 18 the combination.

Results · Original publisher PDF, methods and Tables 1–2
MeasureResultComparison, timing and statistics
Visual acuityRetinalamin alone 0.71 ± 0.05 to 0.76 ± 0.04. Combination 0.76 ± 0.05 to 0.88 ± 0.04.
Electroretinogram a-wave amplitudeRetinalamin alone 21.2 ± 1.5 to 28.1 ± 1.7 µV. Combination 21.4 ± 1.5 to 33.9 ± 1.5 µV.
Electroretinogram b-wave amplitudeRetinalamin alone 173.7 ± 8.1 to 222.7 ± 6.6 µV. Combination 172.8 ± 8.6 to 250.0 ± 7.3 µV.

The combination adds two preparations and a different procedure. The report supplies no treatment-specific estimate for Cortexin or Ventfort Lingval and no between-group confidence intervals.

Source for these results ↗ · Reviewed 2026-11-16

Population / setting
38 patients (76 eyes) with nonexudative macular degeneration: 20 Retinalamin alone, 18 the combination.
Source reviewed
Original Russian article, treatment methods and Tables 1 and 2.
Study limitations
  • The report gives no randomization or masking method and the groups start with different acuity values. The contribution of each added preparation and electrophoresis cannot be isolated.
  • The methods name Retinalamin but also describe Retilin in the adjacent text. The authors leave the mass applied by electrophoresis unspecified.
  • The narrative percentages lack clear denominators. The tables contain no between-group p values or confidence intervals. Independent overlap with other retina cohorts is unspecified.

Reviewed 2026-11-16.

Read the source ↗

Comparison in people · 2013

Ventfort, Cerluten, Svetinorm and Endoluten in cerebral atherosclerosis

The conference table reports total cholesterol of 7.6 mmol/L with standard care, 6.3 with Ventfort and Cerluten, and 5.8 with the four-product combination.

Study notes and original source
2013Human comparative studyRussian-language source

Ventfort, Cerluten, Svetinorm and Endoluten in cerebral atherosclerosis

Oral vascular, brain, liver and pineal polypeptide preparations added to standard therapy · Conference report · company reproduction

D. A. Gorgiladze, R. N. Pinaev, V. A. Aleksandrov · 20th IAGG World Congress, Seoul, 2013. Conference material reproduced by Peptides.

The conference table reports total cholesterol of 7.6 mmol/L with standard care, 6.3 with Ventfort and Cerluten, and 5.8 with the four-product combination.

Results and tables

Reported findings and study design

Moscow, December 2011 to June 2012. Standard treatment alone (514), with Ventfort and Cerluten (319), or with those two plus Svetinorm and Endoluten (416). The Russian methods list two oral capsules each per day for three months for Ventfort, Cerluten and Svetinorm when assigned. Endoluten was one morning capsule daily for two months. Active mass per capsule is unspecified.

Population or model 1,249 adults aged 55–65: 514 standard care, 319 standard care with Ventfort and Cerluten, 416 standard care with all four preparations.

Results · Russian conference reproduction, pp. 8–10, and matching English edition
MeasureResultComparison, timing and statistics
Total cholesterol7.6 ± 0.3 mmol/L standard care, 6.3 ± 0.5 with two products, 5.8 ± 0.6 with four products. Shared baseline 8.7 ± 0.4.Both adjunctive groups are marked significant versus standard care. Exact p values are unavailable.
VLDL cholesterol1.22 ± 0.06, 0.92 ± 0.07 and 0.87 ± 0.05 mmol/L, respectively. Shared baseline 1.42 ± 0.07.Both adjunctive groups are marked significant versus standard care.
Reported fatigue64.0%, 32.3% and 12.9%, respectively. Shared baseline 75.6%.Only the four-product group is marked significant versus standard care in the fatigue row.

The authors credit the St. Petersburg Institute of Bioregulation and Gerontology with developing the preparations. The comparison was conducted at the Moscow branch of the Centre for Revitalization and Health. Symptom assessment and statistical methods are incompletely reported. The Seoul report describes two comparisons from the same Moscow center. Recruitment dates overlap and participant-level linkage is unavailable.

Source for these results ↗ · Reviewed 2026-11-16

Population / setting
1,249 adults aged 55–65: 514 standard care, 319 standard care with Ventfort and Cerluten, 416 standard care with all four preparations.
Source reviewed
Authors’ conference material, Russian reproduction, PDF pages 8–10, methods and Tables 1–2. English and Russian editions describe the same comparison.
Study limitations
  • The authors excluded statin users and people with prior stroke. The comparison provides no individual estimates for Svetinorm or Endoluten.
  • Both editions name Svetinorm in the four-product group and outcome tables. The English dosing list instead says Suprefort. The schedule below follows the Russian methods.
  • The table gives one shared pretreatment column. Methods of allocation and masking, timing of the reported tables and adverse-event ascertainment are unspecified.
  • Table 1 repeats the triglyceride heading with values of unclear identity. The cholesterol, VLDL and first triglyceride rows are legible.
  • The Seoul report describes two comparisons from the same Moscow center. Recruitment dates overlap and participant-level linkage is unavailable.

Reviewed 2026-11-16.

Read the source ↗

Observational study · 2012

Oral peptide combinations for prostate symptoms in Agent Orange-exposed veterans

In 150 veterans, mean prostate symptom score (IPSS) fell from 20.94 to 8.46 (p<0.01) and urinary flow increased from 4.9 to 9.1 mL/s (p<0.001). This before-and-after comparison tested four oral products together.

Study notes and original source
2012Uncontrolled human reportFull text available

Oral peptide combinations for prostate symptoms in Agent Orange-exposed veterans

Veziliut, Vezugen, Kristagen and Ventfort as named in the paper. Branded oral preparations.

Hoàng Văn Huấn, Phạm Khắc Linh, Nguyễn Như Nghĩa, and colleagues · Journal of Tropical Science and Technology. 2012;(1):85–93.

In 150 veterans, mean prostate symptom score (IPSS) fell from 20.94 to 8.46 (p<0.01) and urinary flow increased from 4.9 to 9.1 mL/s (p<0.001). This before-and-after comparison tested four oral products together.

Results and tables

Reported findings and study design

Prospective, within-person comparison of urinary symptoms, quality of life and urine flow before and after adjunctive treatment. All reported denominators below are 150 at each assessment.

Population or model 150 veterans with benign prostatic hyperplasia. The same 150 are shown before and after treatment.

Dose, route and schedule

The 20-day oral regimen lists Veziliut, Vezugen, Kristagen and Ventfort at 0.2 g each per day. These are amounts of the named products. The paper gives no purified peptide content.

Protocol source ↗ · Original journal PDF, methods and Tables 1–3. Parent program report and Ministry of Defence project citation checked.

Results · Original journal PDF, methods and Tables 1–3. Parent program report and Ministry of Defence project citation checked.
MeasureResultComparison, timing and statistics
International Prostate Symptom Score20.94 ± 8.49 → 8.46 ± 2.78p<0.01
Urinary flow4.9 ± 2.3 → 9.1 ± 2.5 mL/sp<0.001
Urinary symptom quality-of-life item4.10 ± 1.01 → 2.53 ± 0.61p<0.001
Severe urinary symptoms61/150 → 14/150IPSS ≥20. The paper reports 40.7% → 9.3%.

Source for these results ↗ · Reviewed 2026-11-14

Population / setting
150 veterans with benign prostatic hyperplasia. The same 150 are shown before and after treatment.
Source reviewed
Original journal PDF, methods and Tables 1–3. Parent program report and Ministry of Defence project citation checked.
Study limitations
  • There was no concurrent untreated comparator or single-product arm. The results cover the combination.
  • The tested Veziliut lot and its peptide content remain unclear. The two 150-person publications are part of the same parent program, and participant overlap remains unverified.

Reviewed 2026-11-14.

Read the source ↗

Experiment described in a patent · 2016

Ventfort plus Chonsurid: dental bone-healing method — RU2593817C2

The Ventfort case had higher final density but slightly later reported healing, alongside a larger defect.

Ventfort adjunct case · 22 mm defect: healing at 6.5 months; density 211 HU · One 63-year-old patient

Study notes and original source
2016Patent / reported experimentsFull text available

Ventfort plus Chonsurid: dental bone-healing method — RU2593817C2

Patent-defined substance or composition · Patent publication

Format: Original patent text and indexed metadata · Reviewed: Claims, selected reported findings and limitations reviewed; supporting experiments not comprehensively appraised.

Андрей Константинович Иорданишвили, Антон Анатольевич Сериков, Дмитрий Викторович Балин, Анна Геннадьевна Слугина, Владимир Владимирович Самсонов, Борис Лаврович Макеев, Ирина Борисовна Долгова · RU2593817C2 · patent family 56011738

The Ventfort case had higher final density but slightly later reported healing, alongside a larger defect.

Results and tables

Reported patent results

Reported findings

The Ventfort case had higher final density but slightly later reported healing, alongside a larger defect.

Two dental-cyst examples with Chonsurid; one also received branded Ventfort before surgery.

Population or model Two dental-cyst examples with Chonsurid; one also received branded Ventfort before surgery.

Results · Description: timing observations and clinical Examples 1 and 2.
MeasureResultComparison, timing and statistics
Ventfort adjunct case22 mm defect: healing at 6.5 months; density 211 HUOne 63-year-old patient
Chonsurid-only example14 mm defect: healing at 6 months; density 194 HUOne 64-year-old patient
Neutral timing observationLonger intake reportedly did not further accelerate healing; postoperative or shorter preoperative use lacked a marked benefitNo group sizes or effect estimates supplied

These selected cases do not establish faster healing. Defect size, different patients, co-treatment and extract identity prevent attribution to Ventfort or a defined vascular peptide.

Source for these results ↗ · Reviewed 2026-11-06

Population / setting
Two dental-cyst examples with Chonsurid; one also received branded Ventfort before surgery.
Source reviewed
Original patent publication accessed through Google Patents. Claims, selected reported findings and source limitations checked. The results section identifies the examples, tables and any numerical extraction gaps. No complete experimental audit, prosecution review or legal claim construction was performed.
Study limitations
  • The extract brand is not interchangeable with Vasolin, Slavinorm or purified KED, and combined treatment prevents independent attribution.
  • These selected cases do not establish faster healing. Defect size, different patients, co-treatment and extract identity prevent attribution to Ventfort or a defined vascular peptide.
  • Patents record claimed inventions and supporting disclosures. Publication or grant does not establish clinical efficacy, safety or marketing approval. Members of one patent family and related journal reports can describe the same experiments.
  • Status labels are Google Patents index snapshots for the displayed publication or application; each record lists the review date. Official registers and every national family member have not been independently checked. These labels do not establish freedom to operate.

Reviewed 2026-11-06.

Read the source ↗

Comparison in people · 2006

Ventfort: clinical report on a tissue-derived preparation

The 2005–2006 report describes lipid and capillary-fragility outcomes during 10–15 days of adjunctive care.

Study notes and original source
2006Human comparative studyRussian-language source

Ventfort: clinical report on a tissue-derived preparation

Report attributed to · Medical Center, St. Petersburg Institute of Bioregulation and Gerontology

Tissue-derived mixture / named preparation · Institute report — commercial reproduction

St. Petersburg Institute of Bioregulation and Gerontology Medical Center (report attribution) · Institute clinical report (commercial reproduction); 2006 study/report date, not website publication date

The 2005–2006 report describes lipid and capillary-fragility outcomes during 10–15 days of adjunctive care.

Population / setting
49 patients: 27 adjunctive Ventfort; 22 controls; ages 52–84, atherosclerosis or senile purpura.
Source reviewed
Russian report reproduced on a commercial website; population, comparison and reported outcomes checked. Signed original and full protocol not authenticated.
Study limitations
  • The table contains inconsistent sex subtotals. Lipid-table significance is relative to baseline; it does not establish fewer cardiovascular events.
  • Commercially reproduced institute report; independent peer review and independent replication are not established by this document.
  • Short-term reporting without a complete adverse-event protocol cannot establish long-term safety. Preparation equivalence to current products or synthetic peptides is unproven.

Reviewed 2026-10-02.

Read the source ↗

Follow shared publications or research classes. These links do not establish equivalent effects between compounds.

Research collection curated by @PepMariner · editorial standards. Send a source correction ↗

Browse bibliography & PDFs ↗